

**AMENDMENTS TO THE CLAIMS:**

The following listing of claims replaces all prior versions of claims in this application.

1. (currently amended) A method~~Use of an alpha2-adrenoceptor antagonist in the manufacture of a medicament~~ for inhibiting the development of epilepsy, which comprises administering an effective amount of an alpha2-adrenoceptor antagonist to ~~in~~ a patient at risk of developing epilepsy.

2. (currently amended) The method~~use~~ according to claim 1, wherein the alpha2-adrenoceptor antagonist is atipamezole or a pharmaceutically acceptable salt thereof.

3. (currently amended) The method~~use~~ according to claim 1, wherein the alpha2-adrenoceptor antagonist is idazoxan or a pharmaceutically acceptable salt thereof.

4. (currently amended) The method~~use~~ according to claim 1, wherein the alpha2-adrenoceptor antagonist is efaroxan or a pharmaceutically acceptable salt thereof.

5. (currently amended) The method~~use~~ according to claim 1, wherein the alpha2-adrenoceptor antagonist is 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole or a pharmaceutically acceptable salt thereof.

6. (currently amended) The method~~use~~ according to claim 1, wherein the alpha2-adrenoceptor antagonist is an analog chosen from analogs of atipamezole, analogs of idazoxan, and analogs of efaroxan.

7. (currently amended) The ~~method~~use according to claim 1, wherein said risk of developing epilepsy is caused by head trauma, brain ischemia, infection, or neurosurgical operation.